2025/12/01 by Jiangtao Li, Wen‐Xuan Huo, Yang Yang +11 · 1 voice
Medicine · #CAR-T cell therapy research #CNS Lymphoma Diagnosis and Treatment #Lymphoma Diagnosis and Treatment
paper · doi:10.1177/09636897251397046
openalex publication_date 2025/12/01 · openalex created_date 2025/12/16 · openalex updated_date 2026/07/22
In this multicenter study, we aimed to identify the prognostic factors for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patients who received autologous stem cell transplantation (ASCT) in the era of novel agents and chimeric antigen receptor (CAR) T-cell therapy. A total of 82 relapsed/refractory DLBCL patients receiving ASCT across four transplant centers were enrolled. The 3-year probabilities of disease progression, non-relapse mortality (NRM), progression-free survival (PFS), and overall survival (OS) were 23.5%, 2.8%, 73.7%, and 91.4%, respectively. Patients who received Pola-R-CHP before ASCT had a higher disease progression rate (85.7% vs. 18.4%, P = 0.034) and a poorer PFS (0% vs. 79.9%, P < 0.001) after ASCT compared with those who did not receive Pola-R-CHP. Patients who received BTKi before ASCT had a higher disease progression rate (60.0% vs. 18.2%, P = 0.025) and a poorer PFS rate (23.8% vs. 81.8%, P < 0.001) after ASCT compared with those who did not receive BTKi. In multivariate analysis, receiving novel agents before ASCT was independently associated with a higher risk of disease progression and worse PFS. In summary, we observed the heterogeneity of relapsed/refractory DLBCL patients who achieved therapies response and received ASCT, and some of them might not benefit from ASCT.